Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterol. 2022;163(3):649–58.

Article  Google Scholar 

Ezdinli EZ, Gelber R, Desai DV, et al. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology experience. Cancer. 1980;46:2149–53.

Article  CAS  PubMed  Google Scholar 

Xu j, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24:483–495.

Bergquist H, Johnsson A, Hammerlid E, et al. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Alim Pharmacol Ther. 2008;27:385–95.

Article  CAS  Google Scholar 

Cui C, Wu X, Deng L, et al. Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: a propensity score-matched analysis. Thorac Cancer. 2022;13:2041–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.

Article  CAS  PubMed  Google Scholar 

Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48.

Article  CAS  PubMed  Google Scholar 

Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–62.

Article  CAS  PubMed  Google Scholar 

Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.

Article  CAS  PubMed  Google Scholar 

Huang J, Xu B, Liu Y, et al. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer Commun. 2019;39:16.

Article  Google Scholar 

Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832–42.

Article  CAS  PubMed  Google Scholar 

Moehler M, Maderer A, Thuss-Patience PC, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020;31(2):228–35.

Article  CAS  PubMed  Google Scholar 

Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma. The ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z-X, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40:277–88.

Article  CAS  PubMed  Google Scholar 

Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. Br Med J. 2022;377: e068714.

Article  Google Scholar 

Shen L, Kato K, Kim S-B, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40:3065–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29:473–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Chen Z, Bai Y, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nat Med. 2024;30:740–8.

Article  CAS  PubMed  Google Scholar 

Chen W-W, Lin C-C, Huang T-C, et al. Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy. Anticancer Res. 2013;33:4123–8.

CAS  PubMed  Google Scholar 

Saad AM, Al-Husseini MJ, Elgebaly A, et al. Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study. Exp Rev Gastroenterol Hepatol. 2018;12(4):417–23.

Article  CAS  Google Scholar 

Webb A, Cunningham D, Scharffo JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.

Article  CAS  PubMed  Google Scholar 

Overman MJ, Kazmi SM, Jhamb J, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010;116:1446–53.

Article  CAS  PubMed  Google Scholar 

Li B, Wang R, Zhang T, et al. Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases. Sci Rep. 2020;10:11259.

Article  PubMed  PubMed Central  Google Scholar 

Shi M, Zhai G-Q. Models for predicting early death in patients with stage IV esophageal cancer: a surveillance, epidemiology, and end results-based cohort study. Cancer Control. 2022;29:1–11.

Article  Google Scholar 

Qiu G, Zhang H, Wang F, et al. Patterns of metastasis and prognosis of elderly esophageal squamous cell carcinoma patients in stage IVB: a population-based study. Transl Cancer Res. 2021;10(11):4591–600.

Article  PubMed  PubMed Central  Google Scholar 

Ghaly G, Harrison S, Kamel MK, et al. Predictors of survival after treatment of oligometastases after esophagectomy. Ann Thorac Surg. 2018;105:357–62.

Article  PubMed  Google Scholar 

Li H, Zhang S, Guo J, et al. Hepatic metastasis in newly diagnosed esophageal cancer: a population-based study. Front Oncol. 2021;11:644860.

Article  PubMed  PubMed Central  Google Scholar 

Polee MB, Hop WCJ, Kok TC, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghazy HF, El-Hadaad HA, Wahba HA, et al. Metastatic esophageal carcinoma: prognostic factors and survival. J Gastrointest Cancer. 2022;53(2):446–50.

Article  PubMed  Google Scholar 

Wang J, Suri JS, Allen PK, et al. Factors predictive of improved outcomes with multimodality local therapy after palliative chemotherapy for stage IV esophageal cancer. Am J Clin Oncol. 2016;39(3):228–35.

Article  CAS  PubMed  Google Scholar